Cwm LLC Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Cwm LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 12.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,465 shares of the biotechnology company’s stock after purchasing an additional 164 shares during the quarter. Cwm LLC’s holdings in BioMarin Pharmaceutical were worth $141,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in BMRN. Commonwealth Equity Services LLC grew its holdings in BioMarin Pharmaceutical by 8.3% during the third quarter. Commonwealth Equity Services LLC now owns 7,413 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 568 shares during the period. Xponance Inc. increased its holdings in shares of BioMarin Pharmaceutical by 2.5% in the 3rd quarter. Xponance Inc. now owns 9,169 shares of the biotechnology company’s stock valued at $811,000 after purchasing an additional 226 shares in the last quarter. Stratos Wealth Partners LTD. acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at about $495,000. Forsta AP Fonden boosted its holdings in BioMarin Pharmaceutical by 1.9% during the third quarter. Forsta AP Fonden now owns 37,500 shares of the biotechnology company’s stock worth $3,318,000 after buying an additional 700 shares in the last quarter. Finally, Mackenzie Financial Corp grew its position in BioMarin Pharmaceutical by 20.9% during the third quarter. Mackenzie Financial Corp now owns 36,296 shares of the biotechnology company’s stock worth $3,128,000 after buying an additional 6,280 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Analyst Ratings Changes

BMRN has been the subject of a number of research reports. Citigroup reduced their price target on shares of BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating for the company in a research report on Thursday, April 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $110.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, April 25th. Scotiabank upped their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a report on Thursday, April 25th. Piper Sandler cut their price target on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Finally, Robert W. Baird decreased their price objective on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 30th. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $107.50.

Insider Transactions at BioMarin Pharmaceutical

In related news, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction on Friday, April 12th. The shares were sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the sale, the director now owns 474,994 shares of the company’s stock, valued at approximately $43,347,952.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the sale, the director now directly owns 474,994 shares in the company, valued at approximately $43,347,952.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Erin Burkhart sold 2,286 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $90.00, for a total value of $205,740.00. Following the completion of the transaction, the chief accounting officer now directly owns 16,156 shares in the company, valued at $1,454,040. The disclosure for this sale can be found here. Over the last three months, insiders have sold 103,229 shares of company stock valued at $9,062,967. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Stock Down 1.6 %

Shares of NASDAQ BMRN opened at $82.44 on Monday. The stock has a fifty day moving average price of $86.89 and a 200 day moving average price of $89.02. The company has a market cap of $15.65 billion, a P/E ratio of 77.05, a P/E/G ratio of 1.30 and a beta of 0.34. BioMarin Pharmaceutical Inc. has a 12-month low of $76.02 and a 12-month high of $99.56. The company has a current ratio of 2.74, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. The company’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.11 earnings per share. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.98 EPS for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.